TOPICAL FORMULATIONS EFFICACIOUS FOR WOUND CARE

• US 20190321378A1
• Filed: 07/01/2019
• Published: 10/24/2019
• Est. Priority Date: 02/26/2018
• Status: Active Grant

• Current Assignee: Aisha Chaudhry
• Original Assignee: Aisha Chaudhry
• Inventors: Chaudhry, Aisha
• Granted Patent: US 10,695,356 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/045 Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
• CPC Class Codes: A61K 31/125 Camphor; Nuclear substituted derivatives thereof
• CPC Class Codes: A61K 31/635 having a heterocyclic ring, e.g. sulfadiazine
• CPC Class Codes: A61K 36/61 Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
• CPC Class Codes: A61K 38/1808 Epidermal growth factor [EGF] urogastrone
• CPC Class Codes: A61K 47/06 Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00

Abstract

The disclosed wound-healing formulation adds ingredients from the group consisting of camphor, menthol and eucalyptus to known silver sulfadiazine-based formulations, or to known silver sulfadiazine-and-urogastrone-based formulations, preferably for the topical treatment of skin wounds such as cuts, burns, surgical wounds, etc. Preferred embodiments are in cream form. The disclosed formulation shows unexpected and startling improvement in wound healing rates over expected healing rates using the known silver sulfadiazine-based or silver sulfadiazine-and-urogastrone-based formulations alone.

Claims

1. A topical formulation, comprising:

(a) silver sulfadiazine;

(b) urogastrone; and

(c) at least one ingredient selected from the group consisting of;

(1) camphor;

(2) menthol; and

(3) eucalyptus.

2. The formulation of claim 1, further comprising at least two ingredients selected from the group consisting of:

(1) camphor;

(2) menthol; and

(3) eucalyptus.

3. The formulation of claim 1, in which the formulation includes about 1% silver sulfadiazine.

4. The formulation of claim 1, in which the formulation includes about 0.001% urogastrone.

5. The formulation of claim 1, in which the formulation includes about 0.5% to about 20% camphor.

6. The formulation of claim 1, in which the formulation includes about 1% to about 30% menthol.

7. The formulation of claim 1, in which e formulation includes about 2% to about 10% eucalyptus.

8. The formulation of claim 2, in which the formulation includes about 0.5% to about 20% camphor and about 1% to about 30% menthol.

9. The formulation of claim 2, in which the formulation includes about 0.5% to about 20% camphor and about 2% to about 10% eucalyptus.

10. The formulation of claim 2, in which the formulation includes about 1% to about 30% menthol and about 2% to about 10% eucalyptus.

11. The formulation of claim 2, in which the formulation includes about 1% silver sulfadiazine.

12. The formulation of claim 2, in which the formulation includes about 0.001% urogastrone.

13. The formulation of claim 1, in which the formulation includes about 1% silver sulfadiazine and about 0.001% unrogastrone.

14. The formulation of claim 2, in which the formulation includes about 1% silver sulfadiazine and about 0.001% unrogastrone.

15. The formulation of claim 3, in which the formulation includes about 0.5% to about 20% camphor.

16. The formulation of claim 3, in which the formulation includes about 1% to about 30% menthol.

17. The formulation of claim 3, in which the formulation includes about 2% to about 10% eucalyptus.

18. A topical formulation, comprising:

(a) about 1% silver sulfadiazine;

(b) about 0.001% urogastrone; and

(c) at least one ingredient selected from the group consisting of;

(1) about 0.5% to about 20% camphor;

(2)about 1% to about 30% menthol; and

(3) about 2% to about 10% eucalyptus.

19. The formulation of claim 18, further comprising at least two ingredients selected from the group consisting of:

(1) about 0.5% to about 20% camphor;

(2) about 1% to about 30% menthol; and

(3) about 2% to about 10% eucalyptus.